Business
Charlotte's Web Advances CBD Science Through Landmark Liver Safety Study
Charlotte's Web Advances CBD Science Through Landmark Liver Safety Study Canada...
About this update from Charlotte's Web Holdings, Inc.
[{"type":"text","content":"\n \n \n \n Charlotte's Web Advances CBD Science Through Landmark Liver Safety Study\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Results of Validcare Study of 839 Adults Ingesting CBD Report No Liver Toxicity\n \n \n \n \n BOULDER, Colo.\n \n ,\n \n March 23, 2021\n \n /CNW/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. (\"Charlotte's Web\" or the \"Company\"), the CBD industry pioneer, market leader and a Certified B Corporation, today reports the clinical results of a Validcare study conducted over the past seven months. The study's results reaffirm the safety of Charlotte's Web™ hemp derived CBD extracts. Charlotte's Web and 11 other companies supported the study to provide sound scientific data on liver toxicity to federal and state regulators including U.S Congress and the U.S. Food and Drug Administration (\"FDA\"). Researchers reported of the 839 participants, zero liver toxicity or disease was detected.\n \n \n \n \n \n \n \n \n \n \"We support using clinical science to inform our nation's health regulators, lawmakers, state and federal regulators but most importantly, we believe in using clinical science to build longterm consumer trust,\" said\n \n Deanie Elsner\n \n , Charlotte's Web CEO. \"Relevant science and regulatory oversight should work hand-in-hand for the benefit of all Americans.\"\n \n \n The FDA requested very specific liver toxicity data last March in its letter to Congress. This important Validcare study is responsive to the FDA's request.\n \n \n The study's methodology used a decentralized, observational approach with  adult consumers of full and broad spectrum hemp extracts and CBD isolates. The Company provided Charlotte's Web™ full-spectrum hemp extract products to its recruited participants. Each participating CBD company recruited a cohort of participants who are already CBD users and who have been prior users of CBD for a minimum of 30 days to meet study inclusion criteria. The study called for a minimum of 681 participants t...